Changes in urinary output due to concomitant administration of sacubitril/valsartan and atrial natriuretic peptide in patients with heart failure: a multicenter retrospective cohort study

Table 2 Baseline characteristics after propensity score matching

Factors	ARB + hANP	ARNI + hANP	P value	Std diff
Factors	n = 27	n = 27	P value	Std diff
Basic property
Age (years)	84 (78, 88)	84 (78, 90)^c	0.749^b	0.011
Body Mass Index (kg/m²)	23.5 (20.6, 269)	22.5 (20.0, 24.0)^c	0.539^b	0.120
Clinical laboratory data
Creatinine clearance (mL/min)	30.1 (17.8, 41.0)	28.2 (23.2, 37.0)^c	0.789^b	0.049
Medical history
Atrial fibrillation, n (%)	16 (59)	13 (48)	0.413^a	0.043
Hypertension, n (%)	22 (81)	22 (81)	1.000^a	0.000
Diabetes, n (%)	5 (19)	6 (22)	0.735^a	0.021
Hyperlipidemia, n (%)	4 (15)	9 (33)	0.111^a	0.086
Myocardial infarction, n (%)	5 (19)	5 (19)	1.000^a	0.000
NYHA Classification
Class I, n (%)	1 (4)	2 (7)	0.673^a	0.036
Class II, n (%)	10 (37)	7 (26)	-	0.058
Class III, n (%)	14 (52)	14 (52)	-	0.000
Class IV, n (%)	2 (7)	4 (15)	-	0.052
Oral medication
Loop diuretic, n (%)	21 (78)	20 (74)	0.750^a	0.012
Thiazide diuretic, n (%)	1 (4)	2 (7)	1.000^a	0.036
Tolvaptan, n (%)	14 (52)	14 (52)	1.000^a	0.000
MRA, n (%)	12 (44)	11 (41)	0.783^a	0.015
β blocker, n (%)	15 (56)	13 (48)	0.586^a	0.029
SGLT2 blocker, n (%)	5 (19)	5 (19)	1.000^a	0.000
Nitrate medicine, n (%)	1 (4)	1 (4)	1.000^a	0.000

ARB Angiotensin II receptor blocker, ARNI Angiotensin receptor neprilysin inhibitor, hANP human atrial natriuretic peptide, MRA Mineralocorticoid receptor antagonist, NYHA New York Heart Association, SGLT2 Sodium glucose cotransporter 2, Std diff Standardized difference
^aChi–square test.
^bMann–Whitney U test
^cEach value represents the median (25th, 75th percentile)

ISSN: 2055-0294